Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Urogen Pharma Ltd
(NQ:
URGN
)
13.73
-0.53 (-3.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
389,484
Open
14.06
Bid (Size)
12.00 (3)
Ask (Size)
18.00 (1)
Prev. Close
14.26
Today's Range
13.17 - 14.28
52wk Range
8.690 - 24.13
Shares Outstanding
30,282,880
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
April 17, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
April 15, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Performance
YTD
-9.73%
-9.73%
1 Month
-8.59%
-8.59%
3 Month
-3.78%
-3.78%
6 Month
+21.18%
+21.18%
1 Year
+34.61%
+34.61%
More News
Read More
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
April 03, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Outlook For UroGen Pharma
March 13, 2024
Via
Benzinga
Recap: UroGen Pharma Q3 Earnings
November 14, 2023
Via
Benzinga
Preview: UroGen Pharma's Earnings
November 13, 2023
Via
Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Via
Benzinga
URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023
March 14, 2024
Via
InvestorPlace
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
March 14, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
The Latest Analyst Ratings for UroGen Pharma
October 04, 2023
Via
Benzinga
Earnings Scheduled For March 14, 2024
March 14, 2024
Via
Benzinga
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
March 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
February 26, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Participate at Upcoming Investor Conferences
February 01, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
January 24, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
January 17, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Participate in the B. Riley Healthcare Conference
January 11, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter
December 07, 2023
Via
Benzinga
UroGen Pharma Reports Third Quarter 2023 Financial Results
November 14, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology
November 13, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
November 07, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch
October 09, 2023
Via
Benzinga
Topics
ETFs
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
October 03, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.